← SynDRA
BINDARIT
SynDRA canonical compound SYN0033049 — structure-anchored drug synonym record
| Clinical phase | Phase 2 |
| Primary target(s) | CCL8 |
| Mechanism of action | NFKB pathway inhibitor |
All known targets
Mechanisms of action (all sources)
- NFKB pathway inhibitor
- FABP4 BINDER
- CCL2 INHIBITOR
Drug classes
- Anti-Inflammatory Agents
- Protein Synthesis Inhibitors
Cross-references
Synonyms
- AF-2838
- Bindarit, Angelini Pharmaceuticals
- CCL2 inhibitor (inflammatory disorders/kidney disease), Angelini Pharmaceuticals
- MCP-1 inhibitor (inflammatory disorder/kidney disease), Angelini Pharmaceuticals
- 2-((1-Benzyl-1H-indazol-3-yl)methoxy)-2-methylpropanoic acid
- AF2838
- 2-[(1-benzylindazol-3-yl)methoxy]-2-methylpropanoic acid
- 2-[(1-benzyl-1h-indazol-3-yl)methoxy]-2-methylpropanoic acid
- Propanoic acid, 2-methyl-2-[[1-(phenylmethyl)-1H-indazol-3-yl]methoxy]-
- JQ11LH711M
- Propanoic acid, 2-methyl-2-((1-(phenylmethyl)-1H-indazol-3-yl)methoxy)-
- SMR004701447
- Bindarit [USAN:INN]
- UNII-JQ11LH711M
- BINDARIT [USAN]
- Bindarit (USAN/INN)
- BINDARIT [INN]
- MLS006010421
- MLS006011107
- SCHEMBL187885
- ZINC4594
- CHEMBL2107549
- GTPL11124
- DTXSID30156660
- HMS3656P16
- KUC114730N
- 2-((1-Benzyl-1H-indazol-3-yl)methoxy)-2-methylpropionic acid
- BCP22728
- EX-A4073
- HY-B0498
- s3032
- AKOS016007434
- BCP9000414
- CCG-267750
- DB12739
- SB16551
- NCGC00346710-01
- NCGC00346710-02
Look up BINDARIT in the interactive SynDRA portal →